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INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common form of 
dementia in the ageing population and affects millions 
of people worldwide [1]. At the neuropathological level, 
AD  is  characterized  by  neuronal  cell  loss  and  the 
combined  presence  of  two  lesions  in  the  brain  - 
extracellular  amyloid-beta  (Aβ)  plaques  and 
intracellular  neurofibrillary  tangles  (NFTs)  [2].  The 
extracellular  deposits  contain  aggregated  Aβ  peptides 
[3], while intraneuronal tangles are aggregates of hyper-
phosphorylated  forms  of  the  neurofilament-associated 
protein tau [4]. Evidence suggests that the pathogenesis 
of AD involves deleterious neurotoxic effects of both 
types of aggregates [5;6]. However, numerous studies 
strongly support a critical role of Aβ aggregates in the 
initiation  phase  of  AD  pathogenesis,  while  tau  might 
mediate  toxicity and impairment of neuronal function 
[5-9]. 
 
Aβ  is  a  proteolytically  processed  fragment  of  the 
amyloid precursor protein (APP) [10;11]. It occurs in 
different length variants with peptides of 40 amino acid 
residues  (Aβ40)  and  42  amino  acid  residues  (Aβ42) 
being the most prevalent. The longer Aβ42 variant has a 
much  higher  propensity  to  form  aggregates.  Genetic 
studies  identified  mutations  in  three  genes  that  cause 
familial forms of AD (FAD): APP, presenilin-1 (PS1), 
and presenilin-2 (PS2) [12]. Mutations in each of these 
genes result in elevated levels of Aβ production and/or 
promote  its  aggregation.  This  genetic  correlation 
strongly favours the key role of Aβ in AD. However, 
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mutations in APP and PS are very rare, and the causes 
of  the  much  more  common  late  onset  forms  of  AD 
(LOAD)  are  largely  unidentified.  In  line  with  a 
significant role of Aβ in pathogenesis, recent data show 
that  various  post-translational  modifications  of  Aβ 
promote  its  aggregation  and  therefore  could  play 
important roles in the initiation of LOAD. 
Generation of Aβ by proteolytic processing of APP 
and effects of AD associated mutations 
 
APP  is  a  type  I  membrane  protein  and  ubiquitously 
expressed  in  most  cell  types.  Alternative  mRNA 
splicing  leads  to  several  cell  type  and  development-
specific  isoforms  [2].  In  addition,  two  homologous 
APP-like  proteins  (APLPs)  have  also  been  identified, 
Figure 1: Schematic representation of generation of Aβ by proteolytic processing of APP and the 
familial AD causing APP mutations. (A) Two pathways (β/γ and α/γ) of APP proteolysis. APP can be cleaved 
by either β- or α-secretase, which is then followed by γ-secretase cleavage results in the generation of either the 
p3-fragment (non-amyloidogenic) or an Aβ (amyloigenic pathway). The designation of secretases, substrates and 
products are depicted, (B) Representation of APP familial AD causing mutations that are identified around N- and 
C-terminal and in the middle region of Aβ. The amino acid residues are numbered according to Aβ sequence. The 
swedish mutation (KM>NL) at N-terminus of Aβ  near to β-secretase cleavage site increases the total production 
of Aβ, whereas the mutations C-terminus of Aβ results in increased production of Aβ42 by altering γ-secretase 
activity.  The  mutations  in  the  middle  region  of  Aβ  might  decrease  the  α-secretory  cleavage,  facilitate  the 
amyloidogenic processing, promote the Aβ production and/or increases the propensity of Aβ  aggregation or 
stabilizes the Aβ against clearance by different proteases. 
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that together form a small protein family with important 
physiological  functions  in  perinatal  and  postnatal 
development  and  cell  communication  [13].  However, 
APLPs do not contain the Aβ sequence and thus APP is 
the sole source of Aβ peptides in the brain [14].  
 
Aβ is produced during normal cellular metabolism and 
secreted to the extracellular milieu of the human brain 
and  also  found  in  cerebrospinal  fluid  (CSF)  [15;16]. 
The  presence  of  Aβ  in  the  CSF  of  nondemented 
individuals and in the media from neuronal cell cultures 
during  normal  metabolism  could  indicate  a 
physiological role of Aβ in the central nervous system 
[17]. Suggested physiological function of Aβ includes 
ion  channel  modulation  [18],  kinase  activation  [19], 
regulation  of  cholesterol  transport  [20],  protection 
against metal-induced oxidative damage [21], learning 
and memory [22] and transcriptional regulation of AD-
associated genes [23].  
 
The generation of Aβ is initially starts with a cleavage 
of  APP  by  β-secretase  at  the  N-terminus  of  the  Aβ 
domain  (Figure  1A).  This  cleavage  results  in  the 
shedding of the APP ectodomain and the generation of a 
membrane bound carboxyl (C)-terminal fragment (CTF-
β).  Subsequently,  γ-secretase  mediates  the  apparently 
intramembranous  cleavage  of  CTF-β  resulting  in  the 
liberation of Aβ into conditioned media of cultured cells 
or  extracellular  fluids  of  the  brain  or  the  periphery 
[2;11]. Alternatively, APP can also be cleaved in a non-
amyloidogenic pathway that involves initial cleavage by 
α-secretase  within  the  Aβ  domain  thereby  precluding 
the subsequent generation of Aβ peptides (Figure 1A) 
[24]. 
 
The mutations within APP that causes early onset AD 
(EOAD),  are  all  located  within  or  close  to  the  Aβ 
domain.  Notably,  a  double  mutation  in  APP  at  the 
cleavage site for β-secretase that cause EOAD increases 
the β-secretory cleavage resulting in an overall higher 
production  of  Aβ  peptides  (see  Swedish  mutation, 
Figure  1B)  [25].  Additional  EOAD-associated 
mutations  located  close  to  the  cleavage  site  for  γ-
secretase at c-terminal of Aβ also alter the proteolytic 
processing  of  APP  (Figure  1B).  These  mutations 
increase  the  ratio  of  Aβ42/40  peptides  thereby 
promoting the relative production of Aβ variants with 
higher propensity to aggregate [26]. Mutations found in 
the  middle  of  the  Aβ  domain  might  exert  different 
effects  (Figure  1B),  (1)  they  might  decrease  the  α-
secretory  cleavage  of  APP  thereby  facilitating 
amyloidogenic  processing  of  APP  [27],  (2)  these 
mutations could also increase the aggregation [28], (3) 
and/or alter the degradation by different proteases [29].  
 
Beside the APP gene, two additional genes have been 
identified to contain mutations that lead to EOAD [30]. 
Both genes encode highly homologous PS proteins that 
are  critical  components  of  the  γ-secretase  complex, 
which  includes  three  additional  proteins  such  as 
nicastrin,  APH-1  (anterior  pharynx-defective  1),  and 
PEN-2  (presenilin  enhancer  2)  to  exert  γ-secretase 
activity in cells [31]. The mutations in PS1 or PS2 also 
alter  γ-secretase  activity  and/or  cleavage  specificity, 
resulting in higher ratios of Aβ42/40 [31]. Together, all 
mutations  in  the  three  genes  known  to  be  associated 
with EOAD affect the generation and/or aggregation of 
Aβ  [25;27].  However,  as  mentioned  before  such 
mutations are very rare and mechanisms that increase 
the aggregation and accumulation of Aβ and cause the 
much more common sporadic forms of AD (>95% of all 
cases), are largely unknown. According to the 'amyloid 
hypothesis',  accumulation  of  Aβ  in  the  brain  is  the 
primary influence driving AD pathogenesis. The rest of 
the  pathogenic  events,  including  impaired  synaptic 
function  and cell  communication  [7;32;33],  activation 
of  microglia  and  astrocytes  [34;35],  neuronal  ionic 
homeostasis  and  oxidative  injury  [36],  mitochondrial 
dysfunction [37], altered kinase/phosphatases activities 
leading  to  formation  of  neurofibrillary  tangles 
containing  tau  protein,  is  proposed  to  result  from  an 
imbalance  between  Aβ  production  and  Aβ  clearance 
[38].   
 
Aβ aggregation - routes to neurotoxic assemblies 
 
Amyloid  formation  in  AD  is  conceptualized  as  a 
complex process of protein aggregation, involving the 
misfolding of Aβ into soluble and insoluble assemblies 
[39]. Monomeric Aβ is mainly composed of α-helical 
and/or  unordered  structure,  whereas  the  misfolded 
polymers  are  rich  in  β-sheet  conformation.  The 
conformational  changes  leading  to  the  formation  of 
extended β-sheets promotes homophilic interactions and 
eventually  leads  to  Aβ  oligomer  formation.  Kinetic 
studies  have  suggested  that  misfolding  of  monomeric 
Aβ precedes formation of oligomers, which then serve 
as seeds/nuclei for accelerated fibril growth (Figure 2) 
[40].  
 
A widely accepted concept for the formation of amyloid 
fibrils  is  the  nucleation-dependent  polymerization 
model [41-43], which separates the fibrillization process 
into  a  nucleation  phase  and  an  elongation  phase. 
Nucleation  requires  the  self-association  of  soluble 
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monomers,  which  is  thermodynamically  unfavourable 
and  so  occurs  slowly.  In  the  nucleation  phase, 
monomers  undergo  conformational  changes  and  self-
associate to form oligomeric nuclei that are rich in β-
sheets. Once the nucleus is formed, assembly of larger 
aggregates  and  fibril  elongation,  a  much  more 
favourable process and proceeds rapidly. As a result, the 
kinetics of amyloid fibril formation is well represented 
by a sigmoidal shape with a nucleation phase/lag phase 
followed  by  a  rapid  growth  phase,  followed  by  a 
saturation phase (Figure 2; green curve). The lag phase 
is  determined  by  the  critical  concentration  of  nuclei, 
which  represent  seeds  for  further  growth  of  the 
polymers  finally  resulting  in  mature  fibrils. 
Accordingly,  the  lag  phase  of  aggregation  can  be 
shortened by addition of preformed seeds (Figure 2; red 
curve). 
 
In a landmark discovery, Pike et al., [44], established 
that  innocuous  monomers  of  Aβ  become  neurotoxic 
upon aggregation. It was further shown that toxicity of 
Aβ  involved  self-association  of  monomers  into 
oligomers  and  higher  aggregated  forms  [45].  This  is 
further supported by in vitro [46-48], and in vivo studies 
showing that oligomeric and pre-fibrillar Aβ assemblies 
are potent neurotoxins [5;49;50]. A correlation between 
soluble oligomeric Aβ levels and the extent of synaptic 
loss  and  severity  of  cognitive  impairment  further 
corroborate  the  findings  [7;32].  Thus,  neurotoxicity 
appears to require toxic oligomeric assemblies of Aβ. 
The  formation  of  such  neurotoxic  assemblies  in  the 
brain  generated  due  to  higher  production  and/or 
decreased clearance of Aβ [51;52]. 
 
 
Effect  of  post-translational  modification  on 
aggregates formation, toxicity and clearance 
 
Amyloid plaques in the human AD brain are known to 
contain a heterogeneous mixture of Aβ peptides [53]. In 
addition to main Aβ species (Aβ40 and Aβ42), a variety 
of  post-translationally  modified  variants  have  been 
identified  [54],  including  truncation  [55-58], 
racemization  [59;60],  isomerization  [61;62], 
pyroglutamination  [63;64],  metal  induced  oxidation 
[65] and phosphorylation [66-68]. 
Figure  2:  Nucleation-dependent  polymerization  model  of  amyloid  aggregation.  Amyloid  formation 
consists  of  two  phases:  (i)  a  nucleation  phase/lag  phase,  in  which  monomers  undergo  conformational 
change/misfolding and associate to form oligomeric nuclei, and (ii) a elongation phase/growth phase, in which 
the nuclei rapidly grow by further addition of monomers and form larger polymers/fibrils until saturation. The 
‘nucleation phase’, is thermodynamically unfavourable and occurs gradually, whereas ‘elongation phase’, is much 
more favourable process and proceeds quickly. Thus, kinetics of amyloid formation is well represented by a 
sigmoidal curve with a lag phase followed by rapid growth phase (green curve). The rate limiting step in the 
process is the formation of nuclei/seeds to promote aggregation. Thus, amyloid formation can be substantially 
speedup by the addition of preformed seeds (nuclei). The addition of seeds reduces the lag time and induces 
faster aggregate formation (red curve). 
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The N-terminal truncated variants of Aβ beginning at 
amino acid 3, 11 and 25 are present in senile plaques 
and  vascular  amyloid  deposits  [56;57;57;69-71].  The 
truncated Aβ25-35  is  shown  to  favour  aggregation  in 
vitro  [72].  Due  to  potential  toxic  effects  of  truncated 
Aβ25–35, it has been frequently used for aggregation or 
toxicity  studies  [73].  Racemization  of  Aβ  at  Asp7, 
Asp23 and Ser26 was reported in the human brain and 
aggregation  properties  of  Aβ  were  influenced  by  the 
position of the racemized residue [59;60]. Isomerization 
of  aspartate  residues  at  position  1,  7  and  23  of  Aβ 
results in structural transition of Aβ and also shown to 
occur in vivo [62]. Isomerization of Aβ promotes fibril 
formation  in  vitro  and  resistance  to  proteolytic 
degradation  [61].  In  addition  Aβ  can  undergo 
pyroglutamination  also  resulting  in  faster  aggregation 
[74;75].  
 
Thus,  post-translational  modifications  of  Aβ  could 
promote oligomer and aggregate formation, thereby also 
reducing the degradation by a variety of proteases [76-
79]. Modified Aβ peptides show enhanced cytotoxicity 
as compared to non-modified peptides [73], and serve 
as seeding species for Aβ aggregate formation in vivo 
[66;74;78].  These  post-translationally  modified  Aβ 
variants appear to be present at an early stages of the 
disease [58;66;71;74]. 
 
Extracellular phosphorylation  
 
Phosphorylation  is  an  important  reversible  post-
translational  modification  that  regulates  the  structural 
and  functional  properties  of  proteins  in  health  and 
disease  [80].  Phosphorylation  is  a  key  step  in  the 
regulation of protein activity, cell cycle control, gene 
regulation,  learning  and  memory  [81].  In  addition  to 
intracellular  protein  kinases  (PKs),  extracellular  PK 
activities  have  also  been  described  [82].  These 
extracellular kinases phosphorylate cell-surface proteins 
and  soluble  extracellular  substrates,  and  thus  could 
affect many physiological processes involving cell-cell 
contacts,  cellular  differentiation  and  proliferation,  ion 
transport [82]. Depending on the localization, these PKs 
are differentiated as ecto-PKs and exo-PKs. Ecto-PKs 
are  localized  at  the  external  surface  of  the  plasma 
membrane  (membrane  bound)  where  they  exert  their 
catalytic activity [83-86]. Exo-PKs are secreted/shedded 
to the extracellular milieu [87;88]. Ecto- and Exo-PKs 
can  phosphorylate  extracellular  membrane  bound 
proteins and soluble proteins Both Ecto- and Exo-PKs 
use  extracellular  ATP  as  co-substrate,  which  can  be 
released by intact cells [89;90]. Extracellular ATP plays 
physiological  roles  in  neurite  outgrowth, 
neurotransmission  and  glial  communication  [91].  The 
release  of  extracellular  ATP  is  mediated  by 
metabotropic  (P2Y)  and  ionotropic  (P2X)  receptors, 
both are widely expressed in the nervous system [92]. In 
the brain, extracellular ATP is present in low nanomolar 
concentrations. However, the local ATP concentration 
can  increase  upon  certain  stimuli,  including  synaptic 
activation [89;93], inflammation [94] and ischaemia in 
vivo  [95].  Therefore,  extracellular  phosphorylation  is 
likely to play a role in normal as well as pathological 
processes in the brain. 
 
Phosphorylation of Aβ 
 
A variety of AD associated proteins including APP [96-
98], BACE [99;100], PS [101;102] and tau [103;104], 
are  shown  to  be  phosphorylated.  Phosphorylation  of 
these proteins affects subcellular trafficking, interaction 
with adapter proteins, signal transduction cascades, APP 
processing, Aβ generation and tangle formation. In AD, 
tau is shown to be abnormally hyperphosphorylated at 
several  Ser/Thr  residues.  Hyperphosphorylation  and 
subsequent accumulation of neurofilament subunits is a 
typical feature of the AD brain [105;106]. However, the 
pathophysiological relevance of tau phosphorylation is 
still under debate. 
 
In  silico  analysis  revealed  that  Aβ  contain  potential 
phosphorylation  sites  at  serine  residue  at  8
th  and  26
th 
position and tyrosine residue at 10
th position. Aβ  can 
undergo phosphorylation by protein kinase A and cdc 2 
in vitro [68], as well as by cultured cells and in human 
CSF (Kumar, 2009; URN: urn:nbn:de:hbz:5N-18193).  
 
We  recently  showed  that  Aβ  is  phosphorylated  at 
serine-8  by  extracellular  protein  kinase  A. 
Phosphorylation of Aβ promoted the formation of toxic 
aggregates  [66].  The  formation  of  small  soluble 
oligomers  is  associated  with  the  conformational 
transition of Aβ from α-helical and random coiled state 
to  a  β-sheet  structure,  as  demonstrated  by  circular 
dichroism.  Phosphorylation-state  specific  antibodies 
were  used  in  western-blotting  and 
immunohistochemistry to demonstrate the occurrence of 
phosphorylated  Aβ  in  murine  AD  models  and  AD 
patient’s brain tissue. Notably, these antibodies further 
confirmed  that  phosphorylation  occurs  at  free 
extracellular Aβ rather than at the full-length APP or β-
CTF, the precursors of Aβ peptide. Phosphorylated Aβ 
co-localized  with  non-phosphorylated  Aβ  in 
extracellular plaques [66]. Interestingly, phosphorylated 
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Aβ  appeared  to  be  concentrated  in  the  centre  of 
individual  plaques  and  was  detected  as  early  as  at  2 
months  of  age  in  APP  transgenic  mice,  and  then 
accumulated  with  aging.  The  detection  of 
phosphorylated Aβ in oligomeric assemblies in mouse 
brain homogenates suggested that phosphorylation also 
increases  aggregation  of  Aβ  in  vivo.  Therefore,  we 
hypothesize that phosphorylation of Aβ might act as a 
conformational switch, thereby promoting the formation 
of aggregates. 
 
To test the effect of Aβ phosphorylation on toxicity in 
vivo,  transgenic  Drosophila  models  were  employed. 
Since Drosophila allows the selective expression of Aβ 
independent of its precursor APP [107;108], transgenic 
Drosophila  flies  expressing  either  the  wild  type  Aβ 
(AβWT)  or  pseudophosphorylated  mutant  (AβS8D) 
were generated. When expressing AβWT and AβS8D 
mutant  in  photoreceptor  cells  in  Drosophila  eyes,  the 
pseudophosphorylated  AβS8D  variant  showed 
significant  cell  degeneration  compared  to  AβWT, 
demonstrating  increased  toxicity  of 
pseudophosphorylated  Aβ.  Notably, 
pseudophosphorylated  AβS8D  also  accumulated  to 
much higher levels in aged flies than AβWT, strongly 
indicating increased aggregation. In addition, transgene 
expression  in  the  fly  brain  showed  stronger  age-
dependent  accumulation  of  pseudophoshporylated  Aβ 
peptides as compared to AβWT. The increased toxicity 
of  pseudophosphorylated  Aβ  was  revealed  by  altered 
climbing behaviour upon aging. This progressive age-
dependent  phenotype,  correlates  with  Aβ  peptide 
accumulation, indicating that pseudophosphorylated Aβ 
can  mimic  the  effect  of  phosphorylation  on  Aβ 
aggregation in vivo [66]. 
 
The  Aβ  plaque  formation  could  be  induced  by 
inoculation  of  amyloid  containing  brain  homogenates 
from  human  or  transgenic  mouse  into  brains  of 
monkeys  or  APP  transgenic  mice,  suggesting  the 
occurrence of nucleation-dependent fibrillization in vivo 
[109;110].  As  phosphorylation  of  Aβ  promotes 
oligomer  formation,  phosphorylated  Aβ  oligomers 
could serve as seeds or nuclei that increase the rate of 
aggregation.  In  agreement  with  this  hypothesis,  the 
nuclei of phosphorylated Aβ were capable to promote 
aggregation of non-phosphorylated Aβ in vitro  [66].  
 
Several proteases or peptidases have been reported that 
are able to cleave Aβ and thereby contribute to efficient 
removal of Aβ in the brain [52;111]. It will therefore 
also  be  interesting  to  assess  the  effect  of 
phosphorylation on protease dependent degradation of 
Aβ. 
 
CONCLUSION 
 
Increasing  evidence  suggests  that  phosphorylation  of 
proteins involved in several neurodegenerative diseases 
and  plays  a  serious  role  during  the  pathogenesis 
[67;112;113].  The  role  of  phosphorylation  in 
modulating the aggregation and fibrillogenesis of tau in 
AD  and  α-synuclein  in  Parkinson’s  disease  (PD)  is 
currently  a  subject  of  intense  investigation 
[103;114;115].  Our  studies  provide  evidence  that  Aβ 
can  undergo  phosphorylation.  Phosphorylation 
promotes  conformational  transition  and  formation  of 
toxic  aggregates.  Further,  phosphorylated  Aβ 
aggregates could serve as endogenous seeds triggering 
further  aggregation  of  soluble,  extracellular  Aβ  into 
plaques in the brain. Phosphorylation stabilizes the Aβ 
against degradation by various proteases in vitro and in 
cell  cultures  (Kumar  et  al.,  Unpublished  data).  The 
stabilization  of  Aβ  by  phosphorylation  might  play  a 
crucial  role  in  AD  pathogenesis,  because  it  would 
eventually  result  in  increased  concentrations  of  this 
peptide  in  the  brain.  Therefore,  inhibition  of 
extracellular  kinases  or  stimulation  of  Aβ 
dephosphorylation could be pursued as valuable targets 
to prevent or slow down the progression of AD. Further, 
the detection of phosphorylated Aβ in biological fluids 
could  also  be  explored  for  evaluation  as  biomarkers. 
Together,  phosphorylation  of  Aβ  might  have  very 
important implications for AD pathogenesis and offer 
novel therapeutic avenues. 
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